Transplant ID Clinical Research

Overview

The mission of the UPMC Transplant Infectious Diseases (TID) program is to support the transplant programs in heart, liver, lung, kidney, pancreatic and intestinal and multivisceral transplantation, as well as mechanical circulatory support, by preventing and treating infectious complications in solid organ transplant candidates and recipients.  The physicians in the group have expertise in a variety of transplant infectious disease-related topics, including but not limited to cytomegalovirus, fungal infections, respiratory viral infections, transplantation of patients infected with human immunodeficiency virus, infections with methicillin-resistant Staphylococcus aureus, infections due to Clostridium difficile, mycobacterial infections, and parasitic infections.

Research is integral to the TID mission. Members of the TID group are actively involved in clinical and translational research on a local and national level, and have published extensively on a variety of the above mentioned topics. Their research efforts span infectious conditions and microbes and share a focus on clinical applicability to patients. The clinical research team consists of a Program Director and experienced research staff that include nurses, laboratory specialists, non-health care workers, and grant administrators with expertise in clinical, data management, fiscal and regulatory aspects of all types of research trials.  Ongoing research efforts are funded by both internal and external sources including the National Institutes of Health, Clinical and Translational Scientific Collaboration, internal funding and pharmaceutical industry grants.

The TID group is involved in a variety of research studies addressing several topics including:

  • Novel therapy of cytomegalovirus infection
  • Effects of viral infections on transplanted organs
  • Safety & effectiveness of vaccination in transplant recipients
  • Epidemiology & treatment of influenza in transplant recipients
  • Respiratory viral infections, including rhinovirus in transplant recipients
  • Outcome studies of donor lung bronchial cultures in lung transplant recipients
  • Outcome studies of Staphylococcus aureus bacteremia in transplant recipients
  • Strongyloidiasis in transplant candidates & recipients
  • The use of home intravenous antibiotics in transplant recipients
  • Pre-transplantation screening to decrease the risk of post-transplant infections
  • The use of probiotics to limit recurrences of Clostridium difficile infections
  • Fecal Microbiome Transplants
Division of Infectious Diseases
Academic Administrative Office

818 Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
412-383-7963

Center for Care of Infectious Diseases

Falk Medical Building
3601 Fifth Avenue
Pittsburgh, PA 15213
Patient Appointments: 412-647-7228